全文获取类型
收费全文 | 1518篇 |
免费 | 161篇 |
出版年
2023年 | 22篇 |
2022年 | 35篇 |
2021年 | 55篇 |
2020年 | 32篇 |
2019年 | 42篇 |
2018年 | 47篇 |
2017年 | 41篇 |
2016年 | 50篇 |
2015年 | 107篇 |
2014年 | 95篇 |
2013年 | 125篇 |
2012年 | 131篇 |
2011年 | 100篇 |
2010年 | 58篇 |
2009年 | 45篇 |
2008年 | 82篇 |
2007年 | 54篇 |
2006年 | 47篇 |
2005年 | 35篇 |
2004年 | 31篇 |
2003年 | 29篇 |
2002年 | 35篇 |
2001年 | 25篇 |
2000年 | 21篇 |
1999年 | 22篇 |
1998年 | 11篇 |
1997年 | 12篇 |
1995年 | 5篇 |
1993年 | 6篇 |
1992年 | 21篇 |
1991年 | 24篇 |
1990年 | 23篇 |
1989年 | 18篇 |
1988年 | 19篇 |
1987年 | 8篇 |
1986年 | 11篇 |
1985年 | 6篇 |
1984年 | 7篇 |
1983年 | 14篇 |
1982年 | 8篇 |
1981年 | 14篇 |
1980年 | 10篇 |
1979年 | 15篇 |
1978年 | 16篇 |
1975年 | 8篇 |
1974年 | 5篇 |
1973年 | 10篇 |
1972年 | 9篇 |
1970年 | 4篇 |
1968年 | 4篇 |
排序方式: 共有1679条查询结果,搜索用时 15 毫秒
121.
Hanna M. Vesterinen Peter Connick Cadi M. J. Irvine Emily S. Sena Kieren J. Egan Gary G. Carmichael Afiyah Tariq Sue Pavitt Jeremy Chataway Malcolm R. Macleod Siddharthan Chandran 《PloS one》2015,10(4)
Objective
To develop and implement an evidence based framework to select, from drugs already licenced, candidate oral neuroprotective drugs to be tested in secondary progressive multiple sclerosis.Design
Systematic review of clinical studies of oral putative neuroprotective therapies in MS and four other neurodegenerative diseases with shared pathological features, followed by systematic review and meta-analyses of the in vivo experimental data for those interventions. We presented summary data to an international multi-disciplinary committee, which assessed each drug in turn using pre-specified criteria including consideration of mechanism of action.Results
We identified a short list of fifty-two candidate interventions. After review of all clinical and pre-clinical evidence we identified ibudilast, riluzole, amiloride, pirfenidone, fluoxetine, oxcarbazepine, and the polyunsaturated fatty-acid class (Linoleic Acid, Lipoic acid; Omega-3 fatty acid, Max EPA oil) as lead candidates for clinical evaluation.Conclusions
We demonstrate a standardised and systematic approach to candidate identification for drug rescue and repurposing trials that can be applied widely to neurodegenerative disorders. 相似文献122.
123.
Malcolm R. Macleod Aaron Lawson McLean Aikaterini Kyriakopoulou Stylianos Serghiou Arno de Wilde Nicki Sherratt Theo Hirst Rachel Hemblade Zsanett Bahor Cristina Nunes-Fonseca Aparna Potluru Andrew Thomson Julija Baginskitae Kieren Egan Hanna Vesterinen Gillian L. Currie Leonid Churilov David W. Howells Emily S. Sena 《PLoS biology》2015,13(10)
124.
Sanaz Gabery Nellie Georgiou-Karistianis Sofia Hult Lundh Rachel Y. Cheong Andrew Churchyard Phyllis Chua Julie C. Stout Gary F. Egan Deniz Kirik ?sa Petersén 《PloS one》2015,10(2)
Huntington disease (HD) is a fatal neurodegenerative disorder caused by an expanded CAG repeat in the huntingtin gene. Non-motor symptoms and signs such as psychiatric disturbances, sleep problems and metabolic dysfunction are part of the disease manifestation. These aspects may relate to changes in the hypothalamus, an area of the brain involved in the regulation of emotion, sleep and metabolism. Neuropathological and imaging studies using both voxel-based morphometry (VBM) of magnetic resonance imaging (MRI) as well as positron emission tomography (PET) have demonstrated pathological changes in the hypothalamic region during early stages in symptomatic HD. In this investigation, we aimed to establish a robust method for measurements of the hypothalamic volume in MRI in order to determine whether the hypothalamic dysfunction in HD is associated with the volume of this region. Using T1-weighted imaging, we describe a reproducible delineation procedure to estimate the hypothalamic volume which was based on the same landmarks used in histologically processed postmortem hypothalamic tissue. Participants included 36 prodromal HD (pre-HD), 33 symptomatic HD (symp-HD) and 33 control participants who underwent MRI scanning at baseline and 18 months follow-up as part of the IMAGE-HD study. We found no evidence of cross-sectional or longitudinal changes between groups in hypothalamic volume. Our results suggest that hypothalamic pathology in HD is not associated with volume changes. 相似文献
125.
Wook Kim Jennifer L. Fiori Yu-Kyong Shin Eitan Okun Jung Seok Kim Peter R. Rapp Josephine M. Egan 《FEBS letters》2014
Pancreatic polypeptide (PP) is a major agonist for neuropeptide Y4 receptors (NPY4R). While NPY4R has been identified in various tissues, the cells on which it is expressed and its function in those cells has not been clearly delineated. Here we report that NPY4R is present in all somatostatin-containing cells of tissues that we tested, including pancreatic islets, duodenum, hippocampus, and hypothalamus. Its agonism by PP decreases somatostatin secretion from human islets. Mouse embryonic hippocampal (mHippo E18) cells expressed NPY4Rs and their activation by PP consistently decreased somatostatin secretion. Furthermore, central injection of PP in mice induced c-Fos immunoreactivity in somatostatin-containing cells in the hippocampus compared with PBS-injected mice. In sum, our results identify PP as a pivotal modulator of somatostatin secretion. 相似文献
126.
Adam Mechler Bradley D. StringerMuhammad S.H. Mubin Egan H. DoevenNicholas W. Phillips Jesse Rudd-SchmidtConor F. Hogan 《生物化学与生物物理学报:生物膜》2014
Lipid-mimetic metallosurfactant based luminophores are promising candidates for labeling phospholipid membranes without altering their biophysical characteristics. The metallosurfactants studied exhibit high structural and physicochemical similarity to phospholipid molecules, designed to incorporate into the membrane structure without the need for covalent attachment to a lipid molecule. In this work, two lipid-mimetic phosphorescent metal complexes are described: [Ru(bpy)2(dn-bpy)]2 + and [Ir(ppy)2(dn-bpy)]+ where bpy is 2,2′-bipyridine, dn-bpy is 4,4′-dinonyl-2,2′-bipyridine and ppy is 2-phenylpyridine. Apart from being lipid-mimetic in size, shape and physical properties, both complexes exhibit intense photoluminescence and enhanced photostability compared with conventional organic fluorophores, allowing for prolonged observation. Moreover, the large Stokes shift and long luminescence lifetime associated with these complexes make them more suitable for spectroscopic studies. The complexes are easily incorporated into dimyristoil-phosphatidyl-choline (DMPC) liposomes by mixing in the organic solvent phase. DLS reveals the labeled membranes form liposomes of similar size to that of neat DMPC membrane. Synchrotron Small-Angle X-ray Scattering (SAXS) measurements confirmed that up to 5% of either complex could be incorporated into DMPC membranes without producing any structural changes in the membrane. Fluorescence microscopy reveals that 0.5% label content is sufficient for imaging. Atomic Force Microscopic imaging confirms that liposomes of the labeled bilayers on a mica surface can fuse into a flat lamellar membrane that is morphologically identical to neat lipid membranes. These results demonstrate the potential of such lipid-mimetic luminescent metal complexes as a new class of labels for imaging lipid membranes. 相似文献
127.
Béatris Mastelic Sohail Ahmed William M. Egan Giuseppe Del Giudice Hana Golding Ian Gust Pieter Neels Steven G. Reed Rebecca L. Sheets Claire-Anne Siegrist Paul-Henri Lambert 《Biologicals》2010,38(5):594-601
For decades, the search for new vaccine adjuvants has been largely empirical. A series of new adjuvants and related formulations are now emerging that are acting through identified immunological mechanisms. Understanding adjuvant mechanism of action is crucial for vaccine design, since this allows for directing immune responses towards efficacious disease-specific effector mechanisms and appropriate memory. It is also of great importance to build new paradigms for assessing adjuvant safety at development stages and at regulatory level. This report reflects the conclusions of a group of scientists from academia, regulatory agencies and industry who attended a conference, organized by the International Association for Biologicals (IABS), on the mode of action of adjuvants on 29–30 April 2010 in Bethesda, Maryland, USA, particularly focusing on how understanding adjuvants mode of action can impact on the assessment of vaccine safety and help to develop target-specific vaccines. More information on the conference output can be found on the IABS website, http://www.iabs.org/. 相似文献
128.
In eukaryotic cells, neutral lipids serve as major energy storage molecules; however, in Plasmodium falciparum, a parasite responsible for causing malaria in humans, neutral lipids may have other functions during the intraerythrocytic stage of the parasite life cycle. Specifically, experimental data suggest that neutral lipid structures behave as a catalyst for the crystallization of hemozoin, a detoxification byproduct of several blood-feeding organisms, including malaria parasites. Synthetic neutral lipid droplets (SNLDs) were produced by depositing a lipid blend solution comprised of mono- and diglycerides onto an aqueous surface. These lipid droplets are able to mediate the production of brown pigments that are morphologically and chemically identical to hemozoin. The partitioning of heme into these SNLDs was examined by employing Nile Red, a lipid specific dye. Soluble ferriprotoporphyrin IX was observed to spontaneously localize to the lipid droplets, partitioning in a pH-dependent manner with an estimated log P of 2.6. Interestingly, the pH profile of heme partitioning closely resembles that of β-hematin formation. Differential scanning calorimetry and kinetic studies demonstrated that the SNLDs provide a unique environment that promotes hemozoin formation. SNLD-mediated formation of the malaria pigment displayed an activation energy barrier lower than those of individual lipid components. In particular, lipid droplets composed of diglycerides displayed activation barriers lower than those composed of monoglycerides. This difference was attributed to the greater fluidity of these lipids. In conjunction with the known pattern of lipid body proliferation, it is suggested that neutral lipid structures within the digestive vacuole not only are the location of in vivo hemozoin formation but are also essential for the survival of the parasite by functioning as a kinetically competent and site specific mediator for heme detoxification. 相似文献
129.
130.
Caitlin C Otto Tanya M Cunningham Michael R Hansen Shelley E Haydel 《Annals of clinical microbiology and antimicrobials》2010,9(1):1-13